DB-1310 by Duality Biologics (Shanghai) for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

Federal Lawsuit Challenges Mask Ban in Suburban New York County

A disability rights organization is challenging a suburban New York ban on wearing masks in public except for health and religious reasons, arguing it is

August 24, 2024

New cardiovascular risk model could greatly decrease use of statins and increase heart attacks, study warns

If millions of Americans no longer qualify for a statin or a blood pressure medication based on a new calculator updated to better predict their

July 29, 2024

Neuroscientists map brain-wide decision-making process in mice

Neuroscientists have revealed how sensory input is transformed into motor action across multiple brain regions in mice.

September 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.